Our luciferase, co-immunoprecipitation and ChIP assays indicated that either FOXP3 or Smad2/3/4 complex could interact with c-Myc protein or/and its promoter to inhibit c-Myc in HCC cells. Here, SMAD2 is linked to hepatocellular carcinoma.